Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Brändle

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Clinical Endocrinology|November 24, 2006
The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapyChristoph Schmid, Michael Brändle
Praxis|September 14, 2022
[Hypercalcemia - Diagnosis and Management]Markus Koster, Michael Brändle
Current Medical Research and Opinion|August 25, 2004
The CORE Diabetes ModelMichael Brändle, William H Herman
Praxis|September 22, 2016
[Not Available]Dorothee Anthony, Markus Diethelm, Michael Brändle
Praxis|May 29, 2019
[Rapid Resolution of Symptomatic Hypercalcaemia]Markus Koster, Simon Ritter, Michael Brändle
Endocrinology, Diabetes & Metabolism Case Reports|July 24, 2025
'Un-thirsty' hypernatremiaMarkus Koster, Katrin Ledergerber, Michael Brändle
European Journal of Internal Medicine|February 24, 2026
Assessing the proportion of patients with type 2 diabetes in tertiary care eligible for combination therapy with GLP-1 receptor agonist and SGLT2 inhibitorAnders B Jensen, Frida Renström, Michael Brändle
Diabetes Care|May 29, 2010
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanibSteffen Böhm, Dagmar Hess, Silke Gillessen, et al.
Clinical Obesity|January 22, 2026
Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique GroupLukas Andereggen, Christoph Schmid, Michael Brändle, et al.
Swiss Medical Weekly|July 15, 2021
Representativeness of the Swiss Diabetes Registry - a single centre analysisTobias Eichmüller, Frida Renström, Katrin Schimke, et al.
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Clinical Endocrinology|November 24, 2006
The influences of hyperprolactinaemia and obesity on cardiovascular risk markers: effects of cabergoline therapyChristoph Schmid, Michael Brändle
Praxis|September 14, 2022
[Hypercalcemia - Diagnosis and Management]Markus Koster, Michael Brändle
Current Medical Research and Opinion|August 25, 2004
The CORE Diabetes ModelMichael Brändle, William H Herman
Praxis|September 22, 2016
[Not Available]Dorothee Anthony, Markus Diethelm, Michael Brändle
Praxis|May 29, 2019
[Rapid Resolution of Symptomatic Hypercalcaemia]Markus Koster, Simon Ritter, Michael Brändle
Endocrinology, Diabetes & Metabolism Case Reports|July 24, 2025
'Un-thirsty' hypernatremiaMarkus Koster, Katrin Ledergerber, Michael Brändle
European Journal of Internal Medicine|February 24, 2026
Assessing the proportion of patients with type 2 diabetes in tertiary care eligible for combination therapy with GLP-1 receptor agonist and SGLT2 inhibitorAnders B Jensen, Frida Renström, Michael Brändle
Diabetes Care|May 29, 2010
Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanibSteffen Böhm, Dagmar Hess, Silke Gillessen, et al.
Clinical Obesity|January 22, 2026
Class III Obesity as a Presenting Syndrome in Prolactinoma Patients: Insights Into Obesity and Metabolic Dysfunction in This Unique GroupLukas Andereggen, Christoph Schmid, Michael Brändle, et al.
Swiss Medical Weekly|July 15, 2021
Representativeness of the Swiss Diabetes Registry - a single centre analysisTobias Eichmüller, Frida Renström, Katrin Schimke, et al.
Pageof 10